PENK Methylation Test for Detecting Bladder Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1549 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-02-03

Study Completion Date

2024-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this clinical trial is to determine the sensitivity and specificity of the EarlyTect® Bladder Cancer test for bladder cancer among patients with hematuria by comparing it to the results of cystoscopy examinations.

The second objective is to compare the clinical performance of EarlyTect® Bladder Cancer test with a NMP22 test and urine cytology test with respect to bladder cancer. By histopathological examination, lesions identified during cystoscopy will be confirmed as malignant or non-malignant by histological examination.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

MDSC Clinical Assay in Finding and Monitoring Cancer Cells in Blood and Urine Samples From Patients With or Without Localized or Metastatic Bladder Cancer

NCT02735512

No Evidence of Disease Stage II Bladder Cancer Stage III Bladder Cancer +2 more

TERMINATED

Development of a Non-Invasive DNA Methylation-Based Assay System for the Risk Assessment of Urothelial Carcinoma

NCT00867620

Bladder Cancer

UNKNOWN

Diagnostic Evaluation of Urine DNA Methylation/Somatic Mutation Profiling for the Detection of Urothelial Carcinoma

NCT04314245

Urothelial Carcinoma Bladder Cancer

COMPLETED

Analytical Specificity of Bladder EpiCheck Test in Healthy Population and Urology Patients Without Prior History or Evidence of Bladder Cancer

NCT06020807

Non Muscle Invasive Bladder Cancer Non-Muscle Invasive Bladder Urothelial Carcinoma

COMPLETED

Urine Sample Collection for Validation of the AnchorDx UriFind™ Bladder Cancer Assay

NCT05643690

Bladder Cancer

SUSPENDED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients with hematuria who are scheduled for cystoscopy will be asked to collect a urine sample for EarlyTect® Bladder Cancer test and will undergo NMP22 and urine cytology tests. The participants will undergo a cystoscopy within 30 days of enrollment. For confirmation of the diagnosis and stage of the tumor, representative histopathology slides from TURBT (Transurethral Resection of Bladder Tumors) may be retrieved and examined by the central pathology laboratory.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bladder Cancer Hematuria; Benign

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hematuria patients aged ≥40

Device: EarlyTect Bladder Cancer test, PENK methylation assay by LTE (Linear Target Enrichment)-qMSP (quantitative methylation-specific real time PCR)

EarlyTect® Bladder Cancer test

Intervention Type DIAGNOSTIC_TEST

A highly accurate and sensitive real-time PCR employing Linear Target Enrichment and Quantitative Methylation-Specific PCR (LTE-qMSP) for measuring PENK methylation in urine DNA to detect bladder cancer in hematuria patients.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

EarlyTect® Bladder Cancer test

A highly accurate and sensitive real-time PCR employing Linear Target Enrichment and Quantitative Methylation-Specific PCR (LTE-qMSP) for measuring PENK methylation in urine DNA to detect bladder cancer in hematuria patients.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Individuals who agree to voluntarily sign an informed consent prior to the initiation of screening
* Adults aged ≥40
* Subjects who have had gross or microscopic hematuria within the 3 months
* Subjects who had no history of bladder cancer and upper tract urothelial cancer
* Subjects who will undergo cystoscopy, NMP22 test, and urine cytology within 1 month after consent

Exclusion Criteria

* Individuals who do not agree to voluntarily sign an informed consent prior to the initiation of screening
* Subjects aged \<40 years
* Subjects with a history of bladder cancer and upper tract urothelial cancer
* Female who are currently menstruating or who have had their last menstrual period within the last 3 days
* Subjects who have undergone invasive procedures in the urinary tract system within the last 3 months
* Subjects with suspected upper urothelial cancer lesions on ultrasound or CT scan
* Subjects who have previously received pelvic radiation therapy
* Subjects who have been diagnosed with other cancers and have received or are currently receiving chemotherapy or immunotherapy within 6 months
* Subjects who require treatment for an active urinary tract infection or vaginitis
* Subjects undergoing prostate cancer treatment or requiring a prostate biopsy
* Subject has any condition which, in the opinion of the investigator should preclude participation in the study

Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No